The Bern Heart and Brain Interaction Study - Interaction Between Brain and Heart in Acute Ischemic Stroke
NCT ID: NCT03720522
Last Updated: 2024-11-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
220 participants
OBSERVATIONAL
2018-12-01
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Brain Heart Interaction in Acute Stroke
NCT02734082
Assessment of One-shot Cardiac-cervical-intracranial MRI in the Etiological Work up of Ischemic Stroke and Transient Ischemic Attacks
NCT04790357
Dynamic Contrast-enhanced Ultrasound Imaging for Cerebral Perfusion Measurement in Acute Ischemic Stroke
NCT02415972
Cardiac CT Angiography in Patients With Acute Ischemic Stroke
NCT06176872
"Hemodynamic Changes During Endovascular Revascularization for Acute Stroke. An Observational Study".
NCT04771468
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Blood vessels can be obstructed by several different mechanisms and identification of this cause is essential to minimize the risk of recurrence. For instance, it may be a blood clot that originally formed in the heart, which breaks off and is carried away by the blood flow into an artery of the brain, which it blocks. The formation of such a clot can be caused by a heart attack, as a heart attack causes reduced mobility of certain parts of the heart, which greatly increases the risk of clot formation. At the same time, a stroke can also induce cardiac changes, for example because of the production of stress hormones secreted during a stroke. These cardiac changes due to stress hormones can greatly look like cardiac changes caused by a heart attack.
As a consequence, when a stroke is caused by a heart attack, it is often very difficult to correctly diagnose the heart attack and therefore treat patients properly. Indeed, symptoms and effects of a stroke and a heart attack may be similar, although these are two completely different medical problems. In order to gain additional knowledge, the investigators aim with this study to make the diagnosis of a heart attack more precise in patients suffering from a stroke.
Hypothesis, primary and secondary objectives:
The investigators postulate that the combination of laboratory, clinical, radiological, echocardiographic and electrophysiological assessments in a predictive score can distinguish myocardial infarction (MI) and neurogenic stunned myocardium (NSM) in stroke patients (MI and NSM defined by cardiac MRI and coronary angiography).
Primary objectives: The primary objective is to assess the prevalence of MI and NSM, with or without wall motion abnormalities, in stroke patients.
Secondary objectives: Secondary objectives aim to develop a predictive score out of laboratory, clinical, radiological (brain MRI), echocardiographic and electrophysiological parameters to identify stroke patients with MI and to distinguish them from patients with NSM.
The project will add important information to the pathogenesis of NSM, the importance of MI in stroke and the clinically relevant question of the management of stroke patients with hsTnT elevations. On one hand, the project offers the chance to improve the identification of patients with relevant coronary sclerosis. The investigators postulate that most of these patients are not identified by current practice. An early identification of these patients is necessary for early treatment and prevention of cardiac events.
On the other hand, the project offers the chance to improve the identification of patients with NSM and to deliver information on clinical relevance of NSM including arrhythmias and wall motion abnormalities. Given the negative association of NSM with outcome after stroke, the identification of NSM patients is the necessary condition for a treatment trial. Beta-blockers could for instance be beneficial for stroke patients with NSM and such a project could have far-reaching consequences on the management of many acute stroke patients in the near future.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1: Patients suffering from acute myocardial infarction
Patients with positive gadolinium late enhancement and positive intramyocardial oedema in the short CMR have an acute myocardial infarction and will be allocated to group 1.
Short cardiovascular MRI (CMR)
A short CMR without additional contrast administration will be performed immediately after the routine brain MRI (at admission or after 24h).
Blood draw
The following study-specific parameters will be tested: neuropeptide Y 1-36, neuropeptide Y 3-36, total plasma metanephrines, metabolomics analysis
Time points for blood draw: at admission (routine), 3h (routine), 24h (routine), 48h, 72h and 3 months.
Urine (collection over 24h)
The following study-specific parameters will be tested: catecholamines.
Time points for collection: at 24h, 72h, and 3 months
Group 2: Patients suffering from chronic myocardial infarction
Patients with elevated (≥ 0.015 mg/L) high sensitive troponin T (hsTnT) levels, positive gadolinium late enhancement and/or positive myocardial infarction suffer from chronic myocardial infarction or significant coronary stenosis. They will be allocated to group 2 and receive coronary angiography in a timely manner according to clinical routine and current guidelines.
Short cardiovascular MRI (CMR)
A short CMR without additional contrast administration will be performed immediately after the routine brain MRI (at admission or after 24h).
Adenosine-perfusion cardiovascular MRI (CMR)
An adenosine-perfusion CMR using contrast medium (gadolinium) will be performed in all patients (except group 1) between 48h and 6 days after admission.
Blood draw
The following study-specific parameters will be tested: neuropeptide Y 1-36, neuropeptide Y 3-36, total plasma metanephrines, metabolomics analysis
Time points for blood draw: at admission (routine), 3h (routine), 24h (routine), 48h, 72h and 3 months.
Urine (collection over 24h)
The following study-specific parameters will be tested: catecholamines.
Time points for collection: at 24h, 72h, and 3 months
Group 3: Patients suffering from stunned neurogenic myocardium
Patients with elevated (≥ 0.015 mg/L) high sensitive troponin T (hsTnT) levels and presence of wall motion abnormalities (WMA) have potential WMA due to neurogenic myocardial stunning. They will be allocated to group 3.
These patients will undergo a follow-up CMR without adenosine-perfusion after 3 months to confirm improvement/normalization of WMA.
Patients with normal (\< 0.015mg/L) hsTnT levels and presence of WMA will also be allocated to group 3.
Short cardiovascular MRI (CMR)
A short CMR without additional contrast administration will be performed immediately after the routine brain MRI (at admission or after 24h).
Adenosine-perfusion cardiovascular MRI (CMR)
An adenosine-perfusion CMR using contrast medium (gadolinium) will be performed in all patients (except group 1) between 48h and 6 days after admission.
Blood draw
The following study-specific parameters will be tested: neuropeptide Y 1-36, neuropeptide Y 3-36, total plasma metanephrines, metabolomics analysis
Time points for blood draw: at admission (routine), 3h (routine), 24h (routine), 48h, 72h and 3 months.
Urine (collection over 24h)
The following study-specific parameters will be tested: catecholamines.
Time points for collection: at 24h, 72h, and 3 months
Group 4: Control
Patients with normal (\< 0.015mg/L) high sensitive troponin T (hsTnT) levels without late enhancement, without myocardial infarction and without wall motion abnormalities will serve as control group and will be classified to group 4.
Short cardiovascular MRI (CMR)
A short CMR without additional contrast administration will be performed immediately after the routine brain MRI (at admission or after 24h).
Adenosine-perfusion cardiovascular MRI (CMR)
An adenosine-perfusion CMR using contrast medium (gadolinium) will be performed in all patients (except group 1) between 48h and 6 days after admission.
Blood draw
The following study-specific parameters will be tested: neuropeptide Y 1-36, neuropeptide Y 3-36, total plasma metanephrines, metabolomics analysis
Time points for blood draw: at admission (routine), 3h (routine), 24h (routine), 48h, 72h and 3 months.
Urine (collection over 24h)
The following study-specific parameters will be tested: catecholamines.
Time points for collection: at 24h, 72h, and 3 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Short cardiovascular MRI (CMR)
A short CMR without additional contrast administration will be performed immediately after the routine brain MRI (at admission or after 24h).
Adenosine-perfusion cardiovascular MRI (CMR)
An adenosine-perfusion CMR using contrast medium (gadolinium) will be performed in all patients (except group 1) between 48h and 6 days after admission.
Blood draw
The following study-specific parameters will be tested: neuropeptide Y 1-36, neuropeptide Y 3-36, total plasma metanephrines, metabolomics analysis
Time points for blood draw: at admission (routine), 3h (routine), 24h (routine), 48h, 72h and 3 months.
Urine (collection over 24h)
The following study-specific parameters will be tested: catecholamines.
Time points for collection: at 24h, 72h, and 3 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age: ≥ 18 and \< 86 years.
* Acute ischemic stroke with symptom onset within 12 hours before admission to hospital.
* Diagnosis of acute ischemic stroke with MRI with diffusion restriction as seen on diffusion weighted imaging.
Exclusion Criteria
* Standard contraindication for performing MRI.
* Severe renal failure (GFR \<40).
18 Years
86 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Insel Gruppe AG, University Hospital Bern
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Simon Jung, PD Dr. med.
Role: STUDY_DIRECTOR
Dep. of Neurology, Inselspital Bern
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bern University Hospital - Inselspital
Bern, Canton of Bern, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-01087
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.